About Us
In HKSH Haematology and Cellular Therapy Centre (Island East), Chimeric Antigen Receptor Therapy (CAR-T) is indicated for the treatment of i) paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse; and ii) adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.